Immunotherapy: Open Access
Open Access

Abstract

HFE Gene Regulation of T-lymphocyte Activity Can be a Potential Target of PCOS

Qi Xu*, Yu-Hang Song, Ya-Nan Chen, Bin-Lu Wang, Guo-Qing Du and Yao Li

Poly-Cystic Ovary Syndrome (PCOS) may be characterized by skeletal muscle abnormalities. Pioglitazone has a certain therapeutic effect on skeletal muscle metabolism in PCOS patients. To investigate the other effects of pioglitazone on skeletal muscle and its mechanism. We used Weighted Gene Co-expression Network Analysis (WGCNA) to identify potential key genes and signaling pathways involved in pioglitazone affecting skeletal muscle in PCOS patients. First, download the chip data of GSE8157 from GEO database. Then, modules related to genes expressed in skeletal muscle of PCOS patients before and after pioglitazone treatment were screened by WGCNA and core genes and differential gene analysis methods were further selected according to the correlation characteristics between modules and clinical manifestations. Finally, the selected genes were enriched for analysis. Four significantly up-regulated genes were screened out by differential gene analysis: MTBP, MAPK14, RBBP6 and PTPRC (Protein Tyrosine Phosphatase Receptor Type C). They are both associated with cell cycle regulation and immune cell (T-cell) antigen receptor signaling. The effect of pioglitazone on skeletal muscle of PCOS patients is mainly reflected in the regulation of abnormal expression of cell cycle and immune cell-related genes. Among them, HFE gene has the most obvious regulation effect on T lymphocyte activity, which may be a potential gene target for the treatment of PCOS.

Published Date: 2022-12-02; Received Date: 2022-11-01